Lucid Diagnostics’ (LUCD) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research note published on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $2.00 price target on the stock.

LUCD has been the topic of several other reports. Ascendiant Capital Markets upped their price objective on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the stock a “buy” rating in a research report on Monday, April 21st. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research note on Wednesday. Finally, BTIG Research set a $2.00 price objective on shares of Lucid Diagnostics in a research report on Tuesday, March 25th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $3.50.

Lucid Diagnostics Stock Up 2.4%

Shares of NASDAQ LUCD opened at $1.26 on Thursday. The stock’s 50-day simple moving average is $1.35 and its two-hundred day simple moving average is $1.13. Lucid Diagnostics has a twelve month low of $0.68 and a twelve month high of $1.80. The firm has a market capitalization of $132.78 million, a P/E ratio of -1.11 and a beta of 1.28.

Institutional Trading of Lucid Diagnostics

Hedge funds have recently bought and sold shares of the company. Berkshire Asset Management LLC PA bought a new position in Lucid Diagnostics during the first quarter valued at approximately $30,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Lucid Diagnostics in the 1st quarter valued at $37,000. Cubist Systematic Strategies LLC bought a new position in shares of Lucid Diagnostics during the 1st quarter valued at $39,000. LPL Financial LLC raised its position in Lucid Diagnostics by 29.1% in the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after purchasing an additional 12,035 shares during the period. Finally, Sunbelt Securities Inc. purchased a new position in Lucid Diagnostics in the 4th quarter worth $67,000. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.